We detected delayed and reduced antibody and T-cell responses after BNT162b2
vaccination in 71 elderly persons (median age 81 years) compared with 123 healthcare …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
has led to the development of various vaccines. Real-life data on immune responses elicited …

Health-care workers were enrolled at Charité-Universitätsmedizin Berlin (n= 107) and older
people were enrolled at an assisted living facility in Berlin, Germany (n= 82).(A) Anti-S1 IgG …

Here we compared SARS-CoV-2-specific antibody and T-cell responses between older
adults (> 80 years old, n= 51) and a younger control group (20–53 years old, n= 46) after …

Abstract Background In December 2020, Israel began a mass vaccination campaign against
coronavirus disease 2019 (Covid-19) by administering the BNT162b2 vaccine, which led to …

Background Despite high vaccine coverage and effectiveness, the incidence of symptomatic
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

ABSTRACT Background SARS-CoV-2 mRNA vaccines have proven high efficacy, however,
limited data exists on the duration of immune responses and their relation to age and side …

Background Vaccine effectiveness against COVID-19 needs to be assessed in diverse real-
world population settings. Methods A cohort study of 805,741 residents in Skåne county …

Objective To assess the antibody response in non-immunocompromised adults after two
doses of BNT162b2. Methods Prospective, single-centre observational study in non …

Objectives The mRNA coronavirus disease 2019 (COVID-19) vaccines have shown high
effectiveness in the prevention of symptomatic COVID-19, hospitalization, severe disease …